2022-501621-20-00已完成3 期
INCB 18424-319: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Purigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN1)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Incyte Corp.
- 入组人数
- 68
- 试验地点
- 31
- 主要终点
- WI-NRS4 response at Week 12, defined as achieving a ≥ 4-point improvement (reduction) in WI-NRS score from baseline.
研究概览
简要总结
To demonstrate the efficacy of ruxolitinib 1.5% cream BID in participants with PN.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Ability to comprehend and willingness to sign a written ICF for the study. Note: A signed written ICF must be obtained for inclusion, see Section 8.1.1 for additional details
- •Age ≥ 18 years at the time of signing the ICF.
- •Clinical diagnosis of PN ≥ 3 months before screening.
- •There are ≥ 6 pruriginous lesions on ≥ 2 different body areas (such as right and left leg) at screening and baseline. Note: The total estimated BSA treatment area must be ≤ 20%.
- •IGA-CPG-S score of ≥ 2 at screening and baseline.
- •Baseline PN-related WI-NRS score ≥
- •Baseline WI-NRS score is defined as the 7-day average of WI-NRS scores before Day 1 (data from a minimum of 4 out of 7 days prior to Day 1 is needed).
- •Removed during Protocol Amendment
- •Willingness to avoid pregnancy or fathering children based on the criteria below. a. Male participants with reproductive potential must agree to take appropriate precautions to avoid fathering children from screening through 90 days (a spermatogenesis cycle) after the last application of study cream and must refrain from donating sperm during this period. Permitted methods in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed. b. Female participants who are WOCBP must have a negative serum pregnancy test at screening and negative urine pregnancy test before the first application of study cream on Day 1 and must agree to take appropriate precautions to avoid pregnancy from screening through 30 days (1 menstrual cycle) after the last application of study cream and must refrain from donating oocytes during this period. Permitted methods in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed. c. A female participant not considered to be of childbearing potential as defined in Appendix A is eligible.
排除标准
- •Acute or chronic pruritus due to a condition other than PN. (Conditions such as: scabies, insect bite, lichen simplex chronicus, psoriasis, acne, folliculitis, habitual picking, lymphomatoid papulosis, chronic actinic dermatitis, dermatitis herpetiformis, sporotrichosis, bullous disease, excoriation syndrome, venous stasis; systemic hematologic disorders [iron-deficiency anemia, polycythemia rubra vera, lymphoma, leukemia]; gastrointestinal disorders [celiac disease, gastric malignancy, obstructive biliary disease; α-1 antitrypsin deficiency]; infections [HIV, hepatitis B and C, mycobacterial]; endocrine disorders [hyperthyroidism]; psychosocial disorders [depression, anxiety], and chronic renal failure.)
- •Current use of a medication known to cause pruritus.
- •History of treatment failure (as assessed by the investigator through study participant interview) for PN or any inflammatory condition with any systemic or topical JAK inhibitors (eg, abrocitinib, baricitinib, deucravacitinib, filgotinib, lestaurtinib, pacritinib, ruxolitinib, tofacitinib, or upadacitinib).
- •Psoralen and ultraviolet A or ultraviolet B therapy within 4 weeks before baseline or Ultraviolet light therapy or prolonged exposure to natural or artificial sources of ultraviolet radiation (eg, sunlight or tanning booth) within 2 weeks before baseline and/or intention to have such exposure during the study that is thought by the investigator to potentially impact the participant's PN.
- •Pregnant or lactating, or considering pregnancy during study participation.
- •History of alcoholism or drug addiction within 1 year before screening or current alcohol or drug use that, in the opinion of the investigator, will interfere with the participant's ability to comply with the application schedule and study assessments
- •Removed during Protocol Amendment
- •Known allergy or reaction to any of the components of the study cream.
- •In the opinion of the investigator, unable or unlikely to comply with the application schedule and study evaluations.
- •Committed to a mental health institution by virtue of an order issued either by the judicial or the administrative authorities.
- •Employees of the sponsor or investigator or otherwise dependents of them.
- •Total estimated BSA treatment area (excluding the scalp) > 20%.
- •The following participants are excluded in France: a. Vulnerable populations according to article L.1121-6 of the French Public Health Code. b. Adults under legal protection or who are unable to express their consent per article L.1121-8 of the French Public Health Code. c. Individuals not affiliated with the social security system.
- •In the EU, participants considered incapacitated (according to CTR Article 31) are excluded from the study.
- •Neuropathic and psychogenic pruritus, such as but not limited to notalgia paresthetica, brachioradial pruritus, small fiber neuropathy, skin picking syndrome, or delusional parasitosis.
- •Active AD lesions (signs and symptoms other than dry skin) within 6 months of screening and baseline.
- •Uncontrolled hypothyroidism or hyperthyroidism at screening as determined by the investigator. Note: If the participant has a history of thyroid disease and is on treatment, the participant must be on a stable thyroid regimen for at least 6 weeks prior to Day
- •Concurrent conditions and history of other diseases: a. Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton's syndrome), pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of pruriginous lesions or assessments of efficacy or compromise participant safety. b. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome). c. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline. d. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chickenpox, clinically infected AD, or impetigo) within 1 week before baseline. e. Unstable asthma or COPD requiring systemic treatment (such as intravenous steroids) or hospital admission or treatment in the emergency department within 3 months of baseline or Stable asthma or COPD requiring the dose equivalent of budesonide more than 720 μg/day (2 puffs BID of a 180-μg dose) or fluticasone more than 440 μg/day (2 puffs BID of a 110-μg dose) or other equivalent inhaled corticosteroids. f. Acute or chronic active HBV or HCV infection (see Section 8.4.5.3). Participants who have recovered or have been successfully treated with no evidence of active HBV or HCV infection and those who are immune due to HBV vaccination can enroll. g. Any underlying condition known to be associated with the clinical presentation of PN that is not under control (stable) prior to the baseline visit.
- •Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data. For example: a. Clinically significant or uncontrolled cardiovascular disease, including unstable angina, acute myocardial infarction or stroke within 6 months from Day 1, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure > 150/90 mmHg) unless approved by the medical monitor/sponsor. b. Participants with or a history of malignancy in the 5 years preceding the baseline visit, except for adequately treated, nonmetastatic nonmelanoma skin cancer. c. Current and/or history of arterial or venous thrombosis, including deep vein thrombosis and pulmonary embolism. d. Current and/or history of active tuberculosis or current and/or history of latent tuberculosis unless adequately treated. e. History of severe anemia, severe thrombocytopenia, or severe neutropenia.
- •Any of the following clinical laboratory test results at screening: a. Cytopenias, defined as follows: − Hemoglobin < 100 g/L (ie, 10 g/dL) − Absolute neutrophil count < 1.5 × 109/L (ie, 1500/μL) − Platelet count < 1 × 1011/L (ie, 100,000/μL) b. Liver function tests: − AST or ALT ≥ 2.5 × ULN − Total bilirubin > 1.5 × ULN unless Gilbert's syndrome c. Estimated glomerular filtration rate < 30 mL/min/1.73 m2 (using the CKD-EPI 2021 Creatinine Equation). d. Positive serology test results at screening for HIV antibody. e. Any other clinically significant laboratory result that, in the opinion of the investigator, poses a significant risk to the participant.
- •Use of any of the following treatments within the indicated washout period before the baseline visit: a. Five half-lives or 12 weeks, whichever is longer – biologic agents (eg, dupilumab). For biologic agents with washout periods longer than 12 weeks (eg, rituximab), consult the medical monitor. b. Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before baseline with another investigational medication or current enrollment in another investigational drug protocol. c. Four weeks for any topical for systemic JAK or TYK2 inhibitor (eg, abrocitinib, baricitinib, deucravacitinib, filgotinib, lestaurtinib, pacritinib, ruxolitinib, tofacitinib, or upadacitinib). d. Four weeks – systemic or intralesional corticosteroids or adrenocorticotropic hormone analogs, cyclosporine, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (eg, mycophenolate or tacrolimus). e. Four weeks for opioid antagonists (eg, naloxone and naltrexone). f. Four weeks for gabapentin, pregabalin, or thalidomide. g. Four weeks for the following: - Paroxetine, fluvoxamine, or other SSRIs - SNRIs - Tricyclic antidepressants h. Four weeks – recreational or medicinal use (topical, inhaled, oral, sublingual, or any other route) of cannabis or cannabinoids (eg, THC, CBD). i. Two weeks – systemic antibiotics and immunizations with live-attenuated vaccines. Note: Live-attenuated vaccines are prohibited during the DBVC period. COVID-19 vaccination is permitted. j. Two weeks – sedating antihistamines. k. Two weeks or 5 half-lives, whichever is longer – strong systemic CYP3A4 inhibitors. l. Two weeks –any topical treatments for PN (other than bland emollients, eg, Aveeno® creams, ointments, sprays, and soap substitutes), such as corticosteroids, calcineurin inhibitors, topical antipruritics (eg, doxepin cream), PDE4 inhibitors, coal tar (shampoo), topical antibiotics, and antibacterial cleansing body wash/soap. m. One week – nonsedating antihistamines used for the treatment of PN.
结局指标
主要结局
WI-NRS4 response at Week 12, defined as achieving a ≥ 4-point improvement (reduction) in WI-NRS score from baseline.
WI-NRS4 response at Week 12, defined as achieving a ≥ 4-point improvement (reduction) in WI-NRS score from baseline.
次要结局
- WI-NRS4 response at Week 4.
- Overall-TS at Week 12, defined as achieving both a WI-NRS4 response and an IGA CPG S TS. (IGA-CPG-S-TS is defined as an IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline.)
- IGA-CPG-S-TS at Week 12.
- WI-NRS4 response on Day 7.
研究者
Clinical Trial Information
Scientific
Incyte Corp.
研究点 (31)
Loading locations...
相似试验
已完成
2 期
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema2022-502827-23-00Incyte Corp.51
招募中
3 期
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to < 18 Years Old) With Moderate Atopic DermatitisAtopic Dermatitis2024-518156-24-00Incyte Corp.150
进行中（未招募）
1 期
Efficacy of ruxolitinib cream in Prurigo nodularis patients: A randomized, placebo-controlled pilot study (PRUX)Patients with symptomatic Prurigo nodularis with active skin manifestationsMedDRA version: 20.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10037083Term: PrurigoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-004739-22-DERheinische Friedrich-Wilhelms-Universität Bonn20
招募中
1 期
Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or EczemaAtopic Dermatitis2025-520514-64-00Rubedo Life Sciences Italy S.R.L.40
招募中
3 期
A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo2022-501668-16-00Pfizer Inc.81